MedTrace Logo

Semaglutide (Wegovy) Treatment for Trichotillomania

NCT07282769 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-04

No results posted yet for this study

Summary

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Conditions

  • Trichotillomania (Hair-Pulling Disorder)
  • Trichotillomania
  • Hair Pulling Disorder
  • Hair Pulling
  • Hair-Pulling Disorder

Interventions

DRUG

Semaglutide

All participants in the study will receive semaglutide (Wegovy).

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jon E Grant · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-02-28
Completion
2027-02-28
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07282769 on ClinicalTrials.gov